Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
April 29, 2024
Cost-Effective DNA Extraction for DNA Barcoding Diverse Biological Samples
Oliver Hyman, Amanda Cass, Ray Enke, et al.
Pain Medicine (Malden, Mass.)
|
July 16, 2024
Tapering Opioids in Patients with Persistent Pain After Cancer Treatment
Taylor Butler, Brooke Lochridge, Karen Hande, et al.
ERJ Open Research
|
October 13, 2022
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
Emily Pei-Ying Lin, Li-Ching Huang, Jennifer Whisenant, et al.
Cancer Treatment and Research Communications
|
March 22, 2025
Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non-small-cell lung cancer
Kibum Kim, Sakil Syeed, Trang Au, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
Sarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 2026
Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686]
Sarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
JTO Clinical and Research Reports
|
February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
Tejas Patil, Alyse Staley, Yunan Nie, et al.
Pharmacoepidemiology and Drug Safety
|
November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis
Margaret Stalker, Connor B Grady, Alex Watts, et al.
JTO Clinical and Research Reports
|
August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
William Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Methods in Molecular Biology (Clifton, N.J.)
|
April 29, 2024
Cost-Effective DNA Extraction for DNA Barcoding Diverse Biological Samples
Oliver Hyman, Amanda Cass, Ray Enke, et al.
Pain Medicine (Malden, Mass.)
|
July 16, 2024
Tapering Opioids in Patients with Persistent Pain After Cancer Treatment
Taylor Butler, Brooke Lochridge, Karen Hande, et al.
ERJ Open Research
|
October 13, 2022
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
Emily Pei-Ying Lin, Li-Ching Huang, Jennifer Whisenant, et al.
Cancer Treatment and Research Communications
|
March 22, 2025
Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non-small-cell lung cancer
Kibum Kim, Sakil Syeed, Trang Au, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 25, 2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
Sarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 1, 2026
Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686]
Sarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
JTO Clinical and Research Reports
|
February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
Tejas Patil, Alyse Staley, Yunan Nie, et al.
Pharmacoepidemiology and Drug Safety
|
November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis
Margaret Stalker, Connor B Grady, Alex Watts, et al.
JTO Clinical and Research Reports
|
August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
William Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Page
of 1